|
|
|
NGM - NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Inc (NGM) is a biotechnology company that specializes in discovering and developing transformative medicines for patients with life-threatening diseases. NGM utilizes its proprietary drug discovery platform to identify novel targets and generate high-quality therapeutics for a variety of conditions, including non-alcoholic steatohepatitis (NASH), cancer, and age-related diseases.
NGM has multiple programs in clinical development, including:
NGM313: A Phase 2b clinical trial investigating NGM313 for the treatment of NASH.
NGM120: A Phase 2 clinical trial for the treatment of advanced solid tumors.
NGM707: A Phase 1b clinical trial for the treatment of patients with metastatic solid tumors.
NGM395: A Phase 1b clinical trial for the treatment of geographic atrophy, a late-stage form of dry age-related macular degeneration.
NGM has partnerships with several pharmaceutical companies, including Merck, Takeda, and Pfizer. Merck is collaborating with NGM on the development of NGM313 for the treatment of NASH, while Takeda is collaborating with NGM on the development of NGM282 for the treatment of NASH and other liver diseases. Pfizer is collaborating with NGM on the development of NGM395 for the treatment of age-related macular degeneration.
NGM is headquartered in South San Francisco, California, and was founded in 2008. The company went public in 2019 and is listed on the NASDAQ Global Select Market under the symbol "NGM".
|
|
|
|
|
